Impact of Respiratory Bacterial Findings on Patients with Chronic Pulmonary Aspergillosis
Table 5
Comparison of clinical characteristics with and without P. aeruginosa in sputum or bronchial washing fluid among study participants (N = 142).
P. aeruginosa
value
Yes
No
(n = 31)
(n = 111)
Age (years)
69 (65–75)
66 (58–74)
0.176
Sex (male)
14 (45.2)
80 (72.1)
0.009
Body mass index (kg/m2)
21.5 (19.1–23.4)
19.1 (17.1–22.1)
0.068
Underlying lung disease
Previous history of pulmonary tuberculosis
20 (64.5)
77 (69.4)
0.664
Nontuberculous mycobacterial pulmonary disease
6 (19.4)
42 (37.8)
0.084
Bronchiectasis
16 (51.6)
30 (27.0)
0.016
Emphysema
6 (19.4)
39 (35.1)
0.127
Interstitial lung disease
0
9 (8.1)
0.206
Previous history of thoracic malignancy
3 (9.7)
5 (4.5)
0.372
Other comorbidities
Diabetes mellitus
10 (32.3)
25 (22.5)
0.345
Congestive heart disease
3 (9.7)
8 (7.2)
0.705
Chronic hepatic insufficiency
2 (6.5)
7 (6.3)
>0.999
Chronic renal insufficiency
2 (6.5)
5 (4.5)
0.647
Rheumatic disease
2 (6.5)
7 (6.3)
>0.999
Previous history of extrathoracic malignancy
3 (9.7)
6 (5.4)
0.410
Chronic pulmonary symptoms
Cough
16 (51.6)
46 (41.4)
0.413
Sputum
17 (54.8)
57 (51.4)
0.840
Breathlessness†
13 (41.9)
44 (39.6)
0.838
Hemoptysis
14 (45.2)
43 (38.7)
0.540
Chest computed tomographic findings
Cavitation
31 (100)
111 (100)
NA
Paracavitary infiltrates
30 (96.8)
103 (92.8)
0.684
Mycetoma
8 (25.8)
33 (29.7)
0.823
Consolidation
2 (6.5)
10 (9.0)
>0.999
Bilateral pulmonary lesions
5 (16.1)
32 (28.8)
0.174
Laboratory findings
White blood cells (μL)
8,380 (6,310−10,410)
7,650 (5,980−9,740)
0.363
C-reactive protein (mg/L)
15.1 (3.3–27.9)
11.0 (2.3–39.5)
0.912
Albumin (g/dL)
4.0 (3.3–4.3)
4.1 (3.7–4.4)
0.378
Data are presented as the median (interquartile range) or number (%). Cases are duplicated. †Breathlessness represents a modified Medical Research Council dyspnea score ≥ 2. Bold values indicate statistical significance at P < 0.05.
